Boston-based Beta Bionics said this week that it closed a $63 million Series B round to support the development of its iLet bionic pancreas system for people with Type 1 diabetes.
The company’s iLet device features an autonomous, dual-chamber infusion pump that is powered by dosing algorithms. Using machine learning and data from a continuous glucose monitor, the algorithms calculate and dose insulin and/or glucagon as needed.
Get the full story at our sister site, Drug Delivery Business News.
The post Beta Bionics raises $63m for bionic pancreas appeared first on MassDevice.